World Journal of
Pharmaceutical and Life Sciences

THE ROLE OF MONOCLONAL ANTIBODIES IN CANCER THERAPY

Morziul Haque*, Ritu Yadav R., Joanna Grace Pullagura, Bhumika Panchal, Kohale Dhiraj Arvind, Mande Earnest Babu, U. Kalyan Kumar and Dharnamani Prasad

ABSTRACT

Monoclonal antibodies (mAbs) have transformed cancer therapy by providing focused techniques that improve the specificity and efficacy of cancer treatments while reducing systemic toxicity. This study examines the critical role that monoclonal antibodies play in oncology, emphasizing the therapeutic uses, mechanisms of action, and potential future developments of these drugs. We go over the processes involved in creating and manufacturing monoclonal antibodies (mAbs), focusing on hybridoma technology, antigen selection, and cutting-edge biotechnological advancements including bispecific antibodies and antibody-drug conjugates (ADCs). The paper explores the various methods that monoclonal antibodies (mAbs) employ to achieve their therapeutic benefits. These mechanisms include direct cytotoxicity, immune response modulation, and growth factor signaling pathway blockage. It is addressed how monoclonal antibodies work in concert with targeted medicines, radiation, and chemotherapy to overcome resistance mechanisms and improve patient outcomes. The review also discusses the difficulties of mAb therapy, such as the emergence of resistance, immunological side effects, and the requirement for individualized treatment plans. This thorough review emphasizes the revolutionary role that monoclonal antibodies have played in the treatment of cancer and points to future research avenues that show promise for developing more effective cancer treatments.

[Full Text Article]   [Download Certificate]